336 related articles for article (PubMed ID: 34949642)
1. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy.
Fernando R; Caldera O; Smith TJ
Proc Natl Acad Sci U S A; 2021 Dec; 118(52):. PubMed ID: 34949642
[TBL] [Abstract][Full Text] [Related]
2. Teprotumumab Divergently Alters Fibrocyte Gene Expression: Implications for Thyroid-associated Ophthalmopathy.
Fernando R; Smith TJ
J Clin Endocrinol Metab; 2022 Sep; 107(10):e4037-e4047. PubMed ID: 35809263
[TBL] [Abstract][Full Text] [Related]
3. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.
Chen H; Mester T; Raychaudhuri N; Kauh CY; Gupta S; Smith TJ; Douglas RS
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1635-40. PubMed ID: 24878056
[TBL] [Abstract][Full Text] [Related]
4. Insulin-Like Growth Factor Pathway and the Thyroid.
Smith TJ
Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.
Smith TJ; Janssen JAMJL
Endocr Rev; 2019 Feb; 40(1):236-267. PubMed ID: 30215690
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy.
Paik JS; Kim SE; Kim JH; Lee JY; Yang SW; Lee SB
Immunobiology; 2020 Mar; 225(2):151902. PubMed ID: 31899052
[TBL] [Abstract][Full Text] [Related]
7. Fibrocyte Participation in Thyroid-Associated Ophthalmopathy Suggests New Approaches to Therapy.
Smith TJ
Ophthalmic Plast Reconstr Surg; 2023 Dec; 39(6S):S9-S18. PubMed ID: 38054981
[TBL] [Abstract][Full Text] [Related]
8. Slit2 Modulates the Inflammatory Phenotype of Orbit-Infiltrating Fibrocytes in Graves' Disease.
Fernando R; Grisolia ABD; Lu Y; Atkins S; Smith TJ
J Immunol; 2018 Jun; 200(12):3942-3949. PubMed ID: 29752312
[TBL] [Abstract][Full Text] [Related]
9. TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy.
Smith TJ
Nat Rev Endocrinol; 2015 Mar; 11(3):171-81. PubMed ID: 25560705
[TBL] [Abstract][Full Text] [Related]
10. Lessons Learned from Targeting IGF-I Receptor in Thyroid-Associated Ophthalmopathy.
Janssen JAMJL; Smith TJ
Cells; 2021 Feb; 10(2):. PubMed ID: 33673340
[TBL] [Abstract][Full Text] [Related]
11. The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy.
Smith TJ
Eye (Lond); 2019 Feb; 33(2):200-205. PubMed ID: 30385883
[TBL] [Abstract][Full Text] [Related]
12. 2021 update on thyroid-associated ophthalmopathy.
Neag EJ; Smith TJ
J Endocrinol Invest; 2022 Feb; 45(2):235-259. PubMed ID: 34417736
[TBL] [Abstract][Full Text] [Related]
13. Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis).
Douglas RS; Mester T; Ginter A; Kim DS
Trans Am Ophthalmol Soc; 2014; 112():26-37. PubMed ID: 25411513
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms in Graves Eye Disease: Apoptosis as the End Point of Insulin-Like Growth Factor 1 Receptor Inhibition.
Morshed SA; Ma R; Latif R; Davies TF
Thyroid; 2022 Apr; 32(4):429-439. PubMed ID: 34927457
[No Abstract] [Full Text] [Related]
15. Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production.
Gillespie EF; Papageorgiou KI; Fernando R; Raychaudhuri N; Cockerham KP; Charara LK; Goncalves AC; Zhao SX; Ginter A; Lu Y; Smith TJ; Douglas RS
J Clin Endocrinol Metab; 2012 May; 97(5):E740-6. PubMed ID: 22399514
[TBL] [Abstract][Full Text] [Related]
16. IGF1 receptor and thyroid-associated ophthalmopathy.
Mohyi M; Smith TJ
J Mol Endocrinol; 2018 Jul; 61(1):T29-T43. PubMed ID: 29273685
[TBL] [Abstract][Full Text] [Related]
17. Increased generation of fibrocytes in thyroid-associated ophthalmopathy.
Douglas RS; Afifiyan NF; Hwang CJ; Chong K; Haider U; Richards P; Gianoukakis AG; Smith TJ
J Clin Endocrinol Metab; 2010 Jan; 95(1):430-8. PubMed ID: 19897675
[TBL] [Abstract][Full Text] [Related]
18. Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy.
Ding Y; Yang S; Gao H
Horm Metab Res; 2021 Apr; 53(4):211-218. PubMed ID: 33853117
[TBL] [Abstract][Full Text] [Related]
19. Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.
Slentz DH; Nelson CC; Smith TJ
Expert Opin Investig Drugs; 2020 Jul; 29(7):645-649. PubMed ID: 32429706
[TBL] [Abstract][Full Text] [Related]
20. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy.
Smith TJ; Hegedüs L; Douglas RS
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):291-302. PubMed ID: 22632366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]